Human Osteoprotegerin ELISA kit
Specifications
| Product Cat#: | EK-07-0347 |
| Product name: | Human Osteoprotegerin ELISA kit |
| Target Name: | OPG |
| Species Reactivity: | Human |
| Product Size: | 48/96 Tests |
| Sensitivity: | 4.5 pg/mL |
| Assay range: | 50-1000 ng/mL |
| Assay Time: | 90 minutes |
| Platform: | Colorimetric Microplate Reader |
| Conjugate: | HRP |
| ELISA Type: | Competitive ELISA |
| Detection Method: | Colorimetric |
| Storage temperature: | Store at 2-8°C |
| Stability: | Stable within the expiration date under suggested storage conditions |
| Shipping condition: | Wet ice |
| Kit Contents: | Microtiter plate ( 1x ), Enzyme conjugate ( 1 vial ), Standard samples ( 6 vials ), |
| Substrates ( A & B, 2 vials ), Stop solution ( 1 vial ), Wash Solution ( 100x, 1 vial ), | |
| Balance solution ( 1 vial ), Instruction ( 1 copy ) | |
| Other Names of Target: | TNFRSF11B; TNFRSF11-B; OCIF; OPG; TR1; Tumor Necrosis Factor Receptor Superfamily Member 11b; Osteoclastogenesis Inhibitory Factor |
Target information
Osteoprotegerin (OPG), also known as osteoclastogenesis inhibitory factor (OCIF), or tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a protein that in humans is encoded by the TNFRSF11B gene. Osteoprotegerin is a cytokine receptor, and a member of the tumor necrosis factor (TNF) receptor superfamily Osteoprotegerin is a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL). By binding RANKL, OPG prevents RANK-mediated nuclear factor kappa B (NF-κB) activation which is a central and rapid acting transcription factor for immune-related genes, and a key regulator of inflammation, innate immunity, and cell survival and differentiation.Osteoprotegerin levels are influenced by voltage-dependent calcium channels Cav1.2.OPG can reduce the production of osteoclasts by inhibiting the differentiation of osteoclast precursors (osteoclasts are related to monocytes/macrophages and are derived from granulocyte/macrophage-forming colony units (CFU-GM)) into osteoclasts and also regulates the resorption of osteoclasts in vitro and in vivo. OPG binding to RANKL on osteoblast/stromal cells, blocks the RANKL-RANK interaction between osteoblast/stromal cells and osteoclast precursors. This has the effect of inhibiting the differentiation of the osteoclast precursor into a mature osteoclast.
Provider
Erpantech Laboratory
